Resiliva (Resmetirom 80 mg / 100 mg) — Affordable Generic for NASH Fibrosis
Safe, bioequivalent alternative to Rezdiffra™ — for patients, distributors & healthcare partners.
Resiliva offers a cost-effective, high-quality generic option for individuals and healthcare systems treating NASH with fibrosis. Designed for global accessibility, Resiliva maintains strict safety, efficacy, and quality standards to ensure reliable therapeutic outcomes..
Resmetirom – A Breakthrough THR-β Agonist for NASH
Resiliva contains resmetirom, the generic equivalent of Rezdiffra™, a first-in-class THR-β agonist indicated for noncirrhotic NASH with fibrosis. Resmetirom works by improving liver fat metabolism, reducing inflammation, and slowing fibrosis progression. Rezdiffra™ received FDA approval on March 14, 2024, backed by the landmark MAESTRO-NASH clinical trial demonstrating significant improvements in liver fat and fibrosis markers.
Backed by Clinical Research
The safety and efficacy of resmetirom are supported by extensive clinical data, particularly the MAESTRO-NASH Phase 3 trial, which established its role as a targeted therapy for NASH fibrosis.
Key Findings:
- Demonstrated reduction of liver fat and fibrosis (MAESTRO-NASH trial)
- FDA-approved as Rezdiffra™ for adults with noncirrhotic NASH with fibrosis
Order Resiliva (For Patients)
Patients worldwide can now order Resiliva (resmetirom tablets) directly from our website with confidence and authenticity verification.
For Patients: Order & Verify
Resiliva provides an affordable alternative to Rezdiffra™, clinically proven to reduce liver fat and slow fibrosis progression. Everest Pharma ensures every patient receives genuine product with verification available after purchase.
Steps to Order:
- Verify Prescription
- Confirm Details
- Place Secure Order
Why Choose Resiliva?
Resiliva is an affordable, bioequivalent version of Rezdiffra™, locally packaged for verified patients and designed to offer reliable therapeutic outcomes at a significantly reduced cost.
Partner with Everest Pharma
Everest Pharma provides Resiliva through cGMP-compliant manufacturing facilities equipped to supply both regulated and semi-regulated markets. Distributors gain access to bulk quantities supported by full documentation, including DMF, COA, and stability reports. Our export division ensures smooth global compliance and dossier support for rapid market entry.
For Distributors: Online Appointment
Globally, 1 in 20 people is affected by NASH/MASH, and treatment options have been limited. Everest Pharma introduces Resiliva — the world’s first generic Resmetirom (INN) tablet. A complete dossier with BE study is ready for partners.
About Resiliva
Resiliva is developed with a mission to expand access to advanced NASH therapy while upholding strict pharmaceutical standards. Manufactured across global cGMP-certified facilities, Resiliva meets international quality requirements for safety, purity, and therapeutic performance. Everest Pharma is committed to affordability, ensuring patients in underserved and emerging markets can access life-changing treatments without financial barriers. By combining innovation, quality assurance, and distribution expertise, Resiliva stands as a reliable, accessible option for NASH fibrosis care worldwide.
